The price of Nuvation Bio Inc. (NYSE:NUVB) shares last traded on Wall Street fell -2.44% to $1.60.
Based on available information, 7 analysts follow Nuvation Bio Inc. (NYSE:NUVB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $4.50. Given the previous closing price of $1.64, this indicates a potential upside of 174.39 percent. NUVB stock price is now -24.85% away from the 50-day moving average and -36.60% away from the 200-day moving average. The market capitalization of the company currently stands at $359.12M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 3 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target reduced from $5 to $2, Jefferies Downgraded its rating from Buy to Hold for Nuvation Bio Inc. (NYSE: NUVB)., while ‘BMO Capital Markets’ rates the stock as ‘Market Perform’.
In other news, FALBERG KATHRYN E, Director bought 43,000 shares of the company’s stock on Dec 05. The stock was bought for $83,962 at an average price of $1.95. Upon completion of the transaction, the Director now directly owns 250,000 shares in the company, valued at $0.4 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 02, Director FALBERG KATHRYN E bought 47,000 shares of the business’s stock. A total of $93,187 was incurred on buying the stock at an average price of $1.98. This leaves the insider owning 207,000 shares of the company worth $0.33 million. Insiders disposed of 2,500,000 shares of company stock worth roughly $4.0 million over the past 1 year. A total of 26.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NUVB stock. A new stake in Nuvation Bio Inc. shares was purchased by BRAIDWELL LP during the first quarter worth $6,597,000. HRT FINANCIAL LP invested $531,000 in shares of NUVB during the first quarter. In the first quarter, ASSENAGON ASSET MANAGEMENT S.A. acquired a new stake in Nuvation Bio Inc. valued at approximately $420,000. AFFINITY ASSET ADVISORS, LLC acquired a new stake in NUVB for approximately $400,000. RBF CAPITAL, LLC purchased a new stake in NUVB valued at around $284,000 in the second quarter. In total, there are 176 active investors with 65.40% ownership of the company’s stock.
A candlestick chart of Nuvation Bio Inc. (NYSE: NUVB) showed a price of $1.5900 on Monday morning. During the past 12 months, Nuvation Bio Inc. has had a low of $1.54 and a high of $6.02. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 48.60, and a quick ratio of 48.60. The fifty day moving average price for NUVB is $2.1290 and a two-hundred day moving average price translates $2.5235 for the stock.
The latest earnings results from Nuvation Bio Inc. (NYSE: NUVB) was released for Sep, 2022.
Nuvation Bio Inc.(NUVB) Company Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
